Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals, Inc. - common stock (NQ: AVIR )

3.190 +0.060 (+1.92%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atea Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 Next >
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
Photo by Danilo Alvesd on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Is There Any Hope for Atea Pharmaceuticals Stock?
If its coronavirus pill project can't be salvaged, it'll be trouble for investors. 
Via The Motley Fool
Exposures COVID-19
3 Beaten-Down Biotech Stocks -- Can They Recover?
Each for reasons of their own, Atea Pharmaceuticals, Omeros, and Novavax have had a very tough time this year. 
Via The Motley Fool
How Atea's Clinical Flop Shakes Up the COVID-19 Pill Market
Merck and Pfizer could benefit from Atea's setback. 
Via The Motley Fool
Exposures COVID-19
Expert Ratings For Atea Pharmaceuticals
Over the past 3 months, 5 analysts have published their opinion on Atea Pharmaceuticals (NASDAQ: 
Via Benzinga
Pfizer Conceding Race in Hospitalized Covid Because of Todos Medical's Triple MOA Antiviral
Photo by Christina Victoria Craft on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a... 
Via Benzinga
3 Top COVID Stocks -- Are They Tricks or Treats?
Ghosts, goblins, ghouls? No, it's three vaccine stocks. 
Via The Motley Fool
Exposures COVID-19
Was Atea Pharmaceutical's Flop Predictable?
Were warning signs there for investors all along? 
Via The Motley Fool
Exposures COVID-19
How The Future Looks For Last Week's Biggest Losers: Vinco Ventures, Atea Pharmaceuticals And More
Last week, the five biggest stock market losers declined between about 75% and 37%. Below is a look at each stock and what they may have in the cards going forward. Galera... 
Via Benzinga
Why Atea Pharmaceuticals Stock Got Crushed This Week
A mid-stage trial miss caused investors to hit the exits this week. 
Via The Motley Fool
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021
Upgrades For Iridium Communications Inc (NASDAQ:IRD... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Mizuho cut QUALCOMM Incorporated (NASDAQ: QCOM) price target from $180 to $165. QUALCOMM shares fell 0.3% to $132.13 in pre-market trading. Deutsche Bank raised the price... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers Xiaobai Maimai Inc. (NASDAQ: HX) shares climbed 42.6% to close at $9.51 on Tuesday. Xiaobai Maimai said Xiaobao An resigned as CEO. Kaival Brands Innovations Group... 
Via Benzinga
Mid-Afternoon Market Update: Dow Surges Over 100 Points; Harmony Biosciences Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded up 0.33% to 35,374.03 while the NASDAQ rose 0.54% to 15,103.67. The S&P also rose, gaining 0.55% to 4,511.35. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Ulta and Atea Rained on the Nasdaq's Parade Tuesday
Even with downward pressure from these two stocks, the Nasdaq Composite moved higher again. 
Via The Motley Fool
Topics Stocks
Exposures COVID-19 US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Redhill Biopharma (NASDAQ:RDHL) stock increased by 18.27% to $5.76 during Tuesday's regular session. Redhill Biopharma's stock is trading at a volume of 2.... 
Via Benzinga
Mid-Day Market Update: Silver Surges 3%; Galera Therapeutics Shares Plunge
Midway through trading Tuesday, the Dow traded up 0.47% to 35,423.05 while the NASDAQ rose 0.59% to 15,110.79. The S&P also rose, gaining 0.61% to 4,513.69. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Atea Pharmaceuticals Is Imploding Today
The company's oral COVID-19 treatment looks like a dud in the mild-to-moderate COVID-19 setting. 
Via The Motley Fool
Exposures COVID-19
AVIR Stock: The Oral Covid-19 Therapy News That Has Atea Pharmaceuticals Plunging Today
Atea Pharmaceuticals (AVIR) stock is on the move Tuesday after providing an update from its Phase 2 Moonsong clinical trial update. 
Via InvestorPlace
Exposures COVID-19
Atea Pharma Stock Crashes After Merck-Rivaling Covid Pill Lags In Midstage Test
Atea Pharmaceuticals said its Covid pill didn't lower viral loads in all patients. 
Via Investor's Business Daily
Mid-Morning Market Update: Markets Open Higher; Johnson & Johnson Boosts FY21 Guidance
Following the market opening Tuesday, the Dow traded up 0.29% to 35,361.89 while the NASDAQ rose 0.31% to 15,068.75. The S&P also rose, gaining 0.39% to 4,503.81. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Entasis Therapeutics Hldg (NASDAQ:ETTX) shares moved upwards by 16.72% to $3.63 during Tuesday's pre-market session. The company's market cap stands at $... 
Via Benzinga
Why Are Atea Pharmaceuticals Shares Plunging Today?
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate... 
Via Benzinga
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral... 
Via Talk Markets
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
Companies working on sorely needed Covid treatments are innovating to keep up. 
Via Investor's Business Daily
3 COVID Stocks That Can Turn $1,000 Into $10,000
Our trio of contributors offer three COVID-19 stocks that will zoom higher, even as we emerge from the pandemic. 
Via The Motley Fool
Exposures COVID-19
Molnupiravir? Not So Fast. What About Tollovir? — Here's Why You Should Know What That Means
Photo by Martin Sanchez on Unsplash Merck (NYSE: MRK) announced last Friday impressive results from its COVID-19 antiviral, molnupiravir. As vaccines are requiring a third booster... 
Via Benzinga
Exposures COVID-19
10 Health Care Stocks With Unusual Options Alerts In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2021
Upgrades Wolfe Research upgraded the previous rating for PACCAR Inc (NASDAQ: 
Via Benzinga
Which COVID-19 Pill Stock Is the Best Buy?
Merck, Pfizer, and Atea are set to do battle next year in the COVID-19 pill market. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.